Onconova Therapeutics (NASDAQ: ONTX) was downgraded by Zacks.com from a “purchase” ranking to a “hold” score in a research note provided to investors on Thursday, Zacks.com reports.
According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It concentrates on finding and also developing little particle drug prospects to deal with cancer cells. The Business‘s products under various phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
A number of various other equities research experts also recently commented on the firm. Noble Financial reissued a “acquire” rating and also provided a $11.00 cost objective on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “acquire” ranking on the stock in a research note on Tuesday, September 28th.
NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day relocating ordinary rate of $2.90 and a two-hundred day relocating ordinary cost of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.
Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly profits outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) revenues per share for the quarter, covering experts’ agreement estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% as well as an unfavorable internet margin of 8,294.27%. The company had profits of $0.06 million throughout the quarter, contrasted to the consensus quote of $0.06 million. Throughout the same quarter in the previous year, the company posted ($ 0.45) EPS. As a group, research analysts forecast that Onconova Therapeutics will post -1.18 EPS for the present year.
A number of hedge funds have lately dealt shares of ONTX. GSA Capital Allies LLP got a brand-new placement in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Resources Management LP got a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC bought a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC purchased a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP bought a brand-new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional investors have 13.36% of the business’s stock.
About Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which participates in the recognition and development of oncology therapeutics. It concentrates on uncovering as well as creating little particle medicine prospects to deal with cancer. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA
. Get a complimentary copy of the Zacks research record on Onconova Therapeutics (ONTX).
For more information concerning research offerings from Zacks Investment Research, browse through Zacks.com.
This instantaneous information alert was produced by narrative scientific research technology and also economic information from Market in order to give visitors with the fastest and also most precise coverage. This story was examined by Market’s editorial team before publication.
SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS TODAY?
Before you think about Onconova Therapeutics, you’ll intend to hear this.
Market keeps an eye on Wall Street’s top-rated and ideal performing research analysts as well as the stocks they advise to their clients on a daily basis. Market has actually identified the five stocks that top analysts are quietly murmuring to their customers to purchase currently before the wider market catches on … and Onconova Therapeutics wasn’t on the listing.
While Onconova Therapeutics presently has a “Buy” rating amongst analysts, top-rated experts think these five stocks are better purchases.
